# Calibrate

Type: Company

Source: Startup Intelligence Brief — https://getstartupbrief.com/entity/calibrate
Canonical HTML page: https://getstartupbrief.com/entity/calibrate

## Timeline

- **2026-06**: Off-Label Drug Mandate — The Vida Health nurse insists Davis try generic naltrexone and bupropion (unapproved for sleep apnea) before approving Zepbound, leading him to abandon the process.
- **2026-05**: Vida Health Assessment — Davis completes blood work, health questionnaires, and multiple video visits with a Vida Health nurse.
- **2026-02**: Employer Imposes Vida Health Requirement — Before filling the prescription, Davis's employer adds a mandatory program with telehealth company Vida Health to manage obesity drug benefits.
- **2025-12**: Zepbound Prescription Issued — David Davis receives a prescription for Zepbound from his primary care doctor to treat obstructive sleep apnea.

## Recent coverage (1 stories)

### Vida Health's 2-Drug Mandate Before $1,000/Month Zepbound Sparks Regulatory Risk
2026-06-14 21:09:45 · Sentiment: Bearish · Impact: 6/10 · Sources: 7

Startup Vida Health’s cost-control strategy—forcing patients to try two off-label generics before covering pricey GLP-1s—is drawing backlash from doctors and could invite regulatory scrutiny, threatening the obesity telehealth sector.
Full story: https://getstartupbrief.com/story/vida-health-regulatory-risk

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getstartupbrief.com/guides/methodology for the full editorial methodology.